New Delhi, February 12 Lincoln Pharmaceuticals announced on Thursday that its consolidated net profit increased by nearly 38 per cent to Rs 29 crore in the third quarter of fiscal 2025-26.
The company had reported a net profit of Rs 21 crore in the year-ago period.
Revenue from operations for the quarter ended December 2025 rose by 13 per cent to Rs 166 crore compared to Rs 147 crore in the third quarter of fiscal 2024-25, the company said in a statement.
The company aims to achieve an annual growth rate of 15-18 per cent, driven by strong performance in the cardiac, diabetic, dermatology, and ENT segments, Lincoln Pharmaceuticals Director Munjal Patel said.
"We are strengthening our R&D pipeline with over 100 new development programs across multiple therapeutic segments and dosage forms, supported by bioequivalence studies and patent initiatives," he added.
The company is targeting an annual revenue of Rs 1,000 crore within the next three years, driven by business expansion into high-value product lines and entry into new markets, he noted.
Shares of the company closed 13.81 per cent up at Rs 604.40 apiece on BSE.